Assessment of plasma expression level of some factors involved in chemo-radiotherapy resistance in response to radiotherapy in non-metastatic rectal cancer patients

Assessment of plasma expression level of the miRNAs involved in chemo-radiotherapy resistance in response to radiotherapy in non-metastatic neoadjuvant rectal cancer patients using microarray technique

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016072618745N9

Enrollment

Registered

2016-07-29

Start date

2016-06-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

locally advanced rectal cancer. Malignant neoplasm of rectum

Interventions

The patients will receive the radiotherapy with the standard dose of 50 Gy divided to 25 sessions (for 5 weeks, 5 sessions per week). The blood samples (10 cc) will be obtained before the radiotherapy

Diagnosis

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patient with locally advanced rectal cancer; Patient with non-metastatic rectal cancer Exclusion criteria: Patients with other cancers; Patients with renal and hepatic disorders

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
The alteration of plasma expression level of the miRNAs. Timepoint: before and after irradation. Method of measurement: microarray technique.	—

Secondary

Measure	Time frame
Plasma expression level of the genes. Timepoint: befor and after irradation. Method of measurement: Real-time PCR.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Ali Mohammad Alizadeh

Cancer Research Center, Cancer Institute of Iran

aalizadeh@sina.tums.ac.ir+98 21 6119 2501

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026